Faith Rahman

Faith Rahman

Auto-generated profile, based on publicly available information

Faith Rahman

Clinical Trials Clinical Operations, University of Kansas Cancer Center, Kansas City, KS 66160, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Cardiology
Verified
Journal Article
Open access
JHJohn B. Hiebert
John B. Hiebert
JVJames Vacek
James Vacek
ZSZubair Shah
Zubair Shah
FRFaith Rahman
Faith Rahman
JPJanet D. Pierce
Janet D. Pierce
Heart failure with preserved ejection fraction (HFpEF) currently represents approximately 50% of heart failure (HF) cases in the USA and is increasingly recognized as a leading cause of morbidity and mortality. Recent data suggest that the prevalence of HFpEF relative to HF with reduced ejection fraction (HFrEF) is increasing at a rate of 1% per year. With an aging population and increasing risk factors such as hypertension, obesity, and diabetes mellitus, HFpEF will soon be the most prevalent HF phenotype. Two-dimensional speckle-tracking echocardiography (STE) has been used to diagnose HFpEF specifically by focusing on the longitudinal systolic function of the left ventricle (LV). Yet there are many patients with HFpEF in whom there are no differences in LV global longitudinal systolic strain, but there are changes in left atrial function and structure. There are several proposed pathophysiological mechanisms for HFpEF such as endothelial dysfunction, interactions among proteins, signaling pathways, and myocardial bioenergetics. Yet only one specific therapy, mineralocorticoid receptor antagonist, spironolactone, is recommended as a treatment for patients with HFpEF. However, spironolactone does not address many of the pathophysiologic changes that occur in HFpEF, thus new novel therapeutic agents are needed. With the limited available therapies, clinicians should use STE to assess for the presence of this syndrome in their patients to provide effective diagnosis and management. (C) 2019 The Authors. ISDN. Published by Elsevier Ltd.

13 January 2021 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
QSQiuhua Shen
Qiuhua Shen
JHJohn B. Hiebert
John B. Hiebert
FRFaith K. Rahman
Faith K. Rahman
KKKathryn J. Krueger
Kathryn J. Krueger
BGBhanu Gupta
Bhanu Gupta
JPJanet D. Pierce
Janet D. Pierce
Shen Q, et al. Int J Heart Fail. 2021 Jul;3(3):160-171. https://doi.org/10.36628/ijhf.2020.0047

20 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DMDiane Mahoney
Diane Mahoney
PCPrabhakar Chalise
Prabhakar Chalise
FRFaith Rahman
Faith Rahman
JPJanet D. Pierce
Janet D. Pierce
GI microbiota has been implicated in producing the inflammatory tumor microenvironment of several cancers. Women with ovarian cancer often report GI-related symptoms at diagnosis although minimal is known about the possible GI bacteria that may trigger pro-tumorigenic immune responses in early EOC. The purpose of this study was to investigate the influences of GI microbiota dysbiosis on serum inflammatory markers during EOC utilizing a rodent model. This experimental design consisted of C57BL/6 mice randomly assigned to either the microbiota dysbiosis group (n = 6) or control group (n = 5). The CD7BL/6 mice assigned to the microbiota dysbiosis group were administered a mixture of broad-spectrum antibiotics (bacitracin and neomycin) for 2 weeks. Both groups were injected intraperitoneally with mouse ovarian epithelial cells that induce ovarian tumorigenesis. Levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were assessed in the serum, and the composition of the GI microbiota in fecal samples was measured using 16S rRNA gene sequencing. Overall CRP serum levels were significantly lower and TNFα levels were significantly higher in the microbiota dysbiosis group compared to the control group. The abundances of microbiota that correlated with CRP serum levels in the combined groups were genus Parabacteroides, Roseburia, and Emergencia and species Ruminococcus faecis, Parabacteroides distasonis, Roseburia Faecis, and Emergencia timonensis. This study provides evidence to support for further investigation of the GI microbial profiles in patients at risk of EOC.

1 May 2019 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
JPJanet Pierce
Janet Pierce
JHJohn B. Hiebert
John B. Hiebert
DMDiane Mahoney
Diane Mahoney
QSQiuhua Shen
Qiuhua Shen
JPJill Peltzer
Jill Peltzer
JPJohn T. Pierce
John T. Pierce
Purpose: Patients with heart failure with preserved ejection fraction (HFpEF) experience fatigue due to impaired myocardial bioenergetics. Cardiomyocyte function depends on the delivery of adenosine triphosphate (ATP), yet there is no convenient bedside method to measure ATP. The purpose of this study was to develop a point-of-contact measurement of ATP that can be used in a clinical setting. Methods: In a laboratory setting, digital finger punctures were conducted using 5 mu l and 10 mu l of capillary blood placed into various amounts of water (H2O). After mixing the solution for 10 s, a Hygiena AquaSnap (TM) Free ATP probe was placed into the solution for 10 s for the detection of ATP. The probe was then placed into the Hygiena luminometer for 15 s, and a value in relative light units (RLU) was obtained. Results: Test samples using 10 mu l of blood diluted from 50 to 500 mls of H2O produced ATP readings of 10,000-7569 RLUs. Using 5 mu l of blood in 375-900 ml of H2O decreased the ATP values to 6459-4189 RLUs. Dilutional volume sparing experiments were conducted with ATP standards to determine the concentration of ATP per RLUs. Conclusion: Patients with HFpEF have increased metabolic demand and impaired myocardial bioenergetics. Thus, identifying a method to measure ATP that is quick and accurate is imperative to accurately assess cellular energy production in this population. Point-of-contact measures, such as ATP, are needed for precision-guided treatment. Data from this study provides the first step toward developing evidence for health policies related to managing fatigue.

22 April 2021 in International Journal of Clinical Trials
Verified
Journal Article
Closed access
PDF file
KKKathryn J. Krueger
Kathryn J. Krueger
FRFaith Rahman
Faith Rahman
QSQiuhua Shen
Qiuhua Shen
JHJohn B. Hiebert
John B. Hiebert
JPJanet D. Pierce
Janet D. Pierce
The COVID-19 pandemic is having a major impact on how current clinical trials are being conducted in the United States. Researchers have experienced the effects of COVID-19 through the halting and delaying of clinical trials, the lack of personal protection equipment (PPE), the closing of clinical sites, and a decrease in participant recruitment. Many clinical trials will have more missing data because of a participant’s inability to attend in-person visits, discontinuation of trial activities, or interruption of time-sensitive study collection data due to COVID-19. All of these events affect the data quality of trials. Government agencies such as the Food and Drug Administration (FDA), centers for disease control and prevention (CDC), and National Institutes Of Health (NIH) have issued recommendations for investigators conducting clinical trials to combat the spread of COVID-19 and to maintain data integrity. Institutions sponsoring clinical trials have also provided guidelines to continue, modify, or pause research studies that are essential to ensure participant and research team safety. Key recommendations include implementing telehealth appointments, wearing a protective mask and face shield, quarantining for 14 days if exposed to COVID-19 or having travelled, and, if possible, maintaining a 6-foot distance. It is also recommended that investigators implement COVID-19 screening questionnaires prior to and during on-site visits. This includes participants and research personnel completing a temperature check and questionnaire screen before in-person data collection. This article will discuss the challenges encountered by researchers conducting clinical trials and provide resources and examples to assist investigators during the COVID-19 pandemic.

1 January 2020 in Journal of Nursing
Verified
Journal Article
Open access
PDF file
QSQiuhua Shen
Qiuhua Shen
DMDiane Mahoney
Diane Mahoney
JPJill Peltzer
Jill Peltzer
FRFaith Rahman
Faith Rahman
KKKathryn J Krueger
Kathryn J Krueger
JPJanet D Pierce
Janet D Pierce
The symptom of fatigue is prevalent among patients with chronic diseases and conditions such as congestive heart failure and cancer. It has a significant debilitating impact on patients’ physical health, quality of life, and well-being. Early detection and appropriate assessment of fatigue is essential for diagnosing, treating, and monitoring disease progression. However, it is often challenging to manage the symptom of fatigue without first investigating the underlying biological mechanisms. In this narrative review, we conceptualize the symptom of fatigue and its relationship with mitochondrial bioenergetics using the National Institute of Health Symptom Science Model (NIH-SSM). In particular, we discuss mental and physical measures to assess fatigue, the importance of adenosine triphosphate (ATP) in cellular and organ functions, and how impaired ATP production contributes to fatigue. Specific methods to measure ATP are described. Recommendations are provided concerning how to integrate biological mechanisms with the symptom of fatigue for future research and clinical practice to help alleviate symptoms and improve patients’ quality of life.